Bristol-Myers Squibb Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher Boerner
- Full Time Employees
- 32,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Route 206 & Province Line Road Princeton NJ United States of America 08543
- IPO Date
- Jun 1, 1972
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.
Company News
Why Women-Run Companies Deserve a Place in Your Portfolio
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
New Strong Buy Stocks for September 24th
QRG Capital Management Inc. Purchases 14,906 Shares of Bristol Myers Squibb Company $BMY
Best Income Stocks to Buy for September 24th
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
BMY vs. ARGX: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
Should Value Investors Buy Bristol Myers Squibb (BMY) Stock?
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years